glp-1 fda shortage declares semaglutide over Big shifts in the landscape GLP-1 Drugs: FDA Sued Over

2026 thresholds: $200 for ALJ, $1,960 for Federal Court

Frequently Asked Questions Henry makes it easy to get the personalized care you need in just a few steps

View image online ( Patient holding injectable A new study uncovered an association between glucagon-like peptide-1 receptor agonist (GLP-1RAs) use and an increased risk of gastroparesis (GP) among patients with Type 2 diabetes

Metformin is a biguanide (insulin sensitizer) while Ozempic is a GLP-1 receptor agonist (hormone mimic)

Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial

GLP-1 Market Segmentation By Type of Molecule Outlook (Revenue, USD Billion, 20212034) Biologics Small Molecules By Active Compound Used Outlook (Revenue, USD Billion, 20212034) Dulaglutide Liraglutide Orforglipron Retatrutide Semaglutide Survodutide Tirzepatide Other Active Compounds By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 20212034) Long-acting GLP-1 Agonist Short-acting GLP-1 Agonist By Route of Administration Outlook (Revenue, USD Billion, 20212034) Oral Parenteral By Target Indication Outlook (Revenue, USD Billion, 20212034) Alzheimers Disease Non-Alcoholic Steatohepatitis Obesity Sleep Apnea Type 2 Diabetes By Regional Outlook (Revenue, USD Billion, 20212034) North America U.S